| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Juan Diego Maya | Q37834063 |
| Mario Faúndez | Q79164112 | ||
| P2093 | author name string | Bruce K Cassels | |
| Patricio Iturriaga-Vásquez | |||
| Jorge Ferreira | |||
| Norbel Galanti | |||
| Antonio Morello | |||
| Arturo Ferreira | |||
| P2860 | cites work | In vitro antiprotozoal activity of extract and compounds from the stem bark of Combretum molle | Q28211573 |
| Ursolic acid as a trypanocidal constituent in rosemary | Q28214033 | ||
| Antiprotozoal activity of Neurolaena lobata | Q43640616 | ||
| Trypanocidal constituents in plants 4. Withanolides from the aerial parts of Physalis angulata | Q43794477 | ||
| Trypanocidal constituents in plants 2.xanthones from the stem bark of Garcinia subelliptica | Q44674495 | ||
| Trypanocidal constituents in plants 3. Leaves of Garcinia intermedia and heartwood of Calophyllum brasiliense. | Q44717820 | ||
| Two new monoterpene glycosides and trypanocidal terpenoids from Dracocephalum kotschyi | Q45092322 | ||
| New norditerpenoids with trypanocidal activity from Vitex trifolia. | Q45172030 | ||
| New sesquiterpene hydroperoxides with trypanocidal activity from Pogostemon cablin | Q81091374 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Trypanosoma cruzi | Q150162 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 601-620 | |
| P577 | publication date | 2006-03-12 | |
| P1433 | published in | Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology | Q15756965 |
| P1476 | title | Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host | |
| P478 | volume | 146 |
| Q104141486 | In vitro studies and preclinical evaluation of benznidazole microparticles in the acute Trypanosoma cruzi murine model |
| Q45213048 | A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information |
| Q44504229 | A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors |
| Q28538813 | A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi |
| Q36935577 | ALDH2 mediates 5-nitrofuran activity in multiple species |
| Q92610556 | Advances in preclinical approaches to Chagas disease drug discovery |
| Q41939272 | Anti-African trypanocidal and antimalarial activity of natural flavonoids, dibenzoylmethanes and synthetic analogues |
| Q58703394 | Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi |
| Q36276857 | Antiparasitic Effect of Vitamin B12 on Trypanosoma cruzi |
| Q41093486 | Aromatic amine N-oxide organometallic compounds: searching for prospective agents against infectious diseases |
| Q47093622 | Benznidazole affects expression of Th1, Th17 and Treg cytokines during acute experimental Trypanosoma cruzi infection. |
| Q28539047 | Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics |
| Q38107034 | Biogenic trypanocidal sesquiterpenes: lead compounds to design future trypanocidal drugs - a mini review |
| Q43183386 | Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox. |
| Q52718692 | Canonical PI3Kγ signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis. |
| Q37310959 | Chagas' disease: an update on immune mechanisms and therapeutic strategies |
| Q63352274 | Chemical Constituents of Anacardium occidentale as Inhibitors of Trypanosoma cruzi Sirtuins |
| Q36571788 | Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi |
| Q35676177 | Clinical aspects of Chagas disease and implications for novel therapies |
| Q36933398 | Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease |
| Q36075925 | Concomitant Benznidazole and Suramin Chemotherapy in Mice Infected with a Virulent Strain of Trypanosoma cruzi |
| Q36933422 | Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease |
| Q34170132 | Current and developing therapeutic agents in the treatment of Chagas disease |
| Q35848992 | Dibenzylideneacetones Are Potent Trypanocidal Compounds That Affect the Trypanosoma cruzi Redox System |
| Q28481694 | Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 |
| Q46099559 | Docking and molecular dynamics simulation of quinone compounds with trypanocidal activity. |
| Q38135446 | Drug discovery for neglected diseases: molecular target-based and phenotypic approaches |
| Q64284562 | Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole |
| Q30096798 | Effects of astaxanthin in mice acutely infected with Trypanosoma cruzi |
| Q59132384 | Efficacy of sertraline against : an in vitro and in silico study |
| Q41410094 | Essential oil of Azorella cryptantha collected in two different locations from San Juan Province, Argentina: chemical variability and anti-insect and antimicrobial activities. |
| Q43010584 | Evaluation of the trypanocidal, cytotoxic and genotoxic activity of styrylquinoline analogs. |
| Q41989175 | Experimental and Clinical Treatment of Chagas Disease: A Review. |
| Q37392826 | Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors |
| Q55478711 | Flavonoids as a Natural Treatment Against Entamoeba histolytica. |
| Q92774155 | Gamma-glutamylcysteine synthetase and tryparedoxin 1 exert high control on the antioxidant system in Trypanosoma cruzi contributing to drug resistance and infectivity |
| Q38611251 | Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benzonidazole in Trypanosoma cruzi |
| Q42945231 | Hypoxia-activated cytotoxicity of benznidazole against clonogenic tumor cells |
| Q56958189 | Identification of dehydrocostus lactone and 4-hydroxy-β-thujone as auxin polar transport inhibitors |
| Q43212004 | In vitro activity of thienyl-2-nitropropene compounds against Trypanosoma cruzi |
| Q34045200 | In vitro and in vivo trypanocidal effects of the cyclopalladated compound 7a, a drug candidate for treatment of Chagas' disease |
| Q39307555 | In vivo infection by Trypanosoma cruzi: a morphometric study of tissue changes in mice. |
| Q38154345 | Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi. |
| Q58584197 | Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents |
| Q35941223 | Induction of oxidative stress in Trypanosoma brucei by the antitrypanosomal dihydroquinoline OSU-40. |
| Q90231350 | Insights into Ergosterol Peroxide's Trypanocidal Activity |
| Q36446085 | Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain. |
| Q43162297 | Mechanism of Trypanosoma cruzi death induced by Cratylia mollis seed lectin. |
| Q42765317 | Mitochondrial dysfunction in Trypanosoma cruzi: the role of Serratia marcescens prodigiosin in the alternative treatment of Chagas disease |
| Q35944953 | Mode of Action of the Sesquiterpene Lactones Psilostachyin and Psilostachyin C on Trypanosoma cruzi |
| Q42110098 | Modulation of biotransformation systems and ABC transporters by benznidazole in rats. |
| Q46710618 | Modulation of oxidative and inflammatory cardiac response by nonselective 1- and 2-cyclooxygenase inhibitor and benznidazole in mice |
| Q64286617 | Molecular Dynamics Simulations of Substrate Release from Trypanosoma cruzi UDP-Galactopyranose Mutase |
| Q37007967 | Molecular and cellular mechanisms involved in the Trypanosoma cruzi/host cell interplay |
| Q57833404 | Molecular modeling of Trypanosoma cruzi glutamate cysteine ligase and investigation of its interactions with glutathione |
| Q57213684 | Nanoencapsulation of benznidazole in calcium carbonate increases its selectivity to Trypanosoma cruzi |
| Q37835034 | Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi |
| Q84919034 | New imidazolidine derivatives as anti-Trypanosoma cruzi agents: structure-activity relationships |
| Q41898218 | Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine |
| Q36212750 | Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma |
| Q33870401 | Novel ruthenium complexes as potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity |
| Q56341364 | One-Electron Reduction Potentials: Calibration of Theoretical Protocols for Morita⁻Baylis⁻Hillman Nitroaromatic Compounds in Aprotic Media |
| Q28547166 | Pharmacophore modeling for anti-Chagas drug design using the fragment molecular orbital method |
| Q58763634 | Phenotypic diversity and drug susceptibility of Trypanosoma cruzi TcV clinical isolates |
| Q46279466 | Physalins B and F, seco-steroids isolated from Physalis angulata L., strongly inhibit proliferation, ultrastructure and infectivity of Trypanosoma cruzi. |
| Q42281830 | Prostaglandin F2α synthase in Trypanosoma cruzi plays critical roles in oxidative stress and susceptibility to benznidazole |
| Q46051350 | Reduction of parasite levels in blood improves pregnancy outcome during experimental Trypanosoma cruzi infection. |
| Q28484352 | Regulation of biotransformation systems and ABC transporters by benznidazole in HepG2 cells: involvement of pregnane X-receptor |
| Q34172530 | Risedronate metal complexes potentially active against Chagas disease. |
| Q28543494 | Ruthenium complex with benznidazole and nitric oxide as a new candidate for the treatment of chagas disease |
| Q30359734 | Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors |
| Q37404837 | Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities |
| Q39068425 | Synthesis and evaluation of antioxidant and trypanocidal properties of a selected series of coumarin derivatives. |
| Q41105200 | Synthesis and pharmaceutical properties of N-acyloxymethyl prodrugs of Allop with potential anti-trypanosomal activity |
| Q58849622 | Synthesis of coumarin–chalcone hybrids and evaluation of their antioxidant and trypanocidal properties |
| Q36109819 | Systematic Review and Meta-analysis of the Pharmacokinetics of Benznidazole in the Treatment of Chagas Disease |
| Q35862244 | The Combination of Vitamin K3 and Vitamin C Has Synergic Activity against Forms of Trypanosoma cruzi through a Redox Imbalance Process |
| Q41840211 | The Involvement of Glutamate Metabolism in the Resistance to Thermal, Nutritional, and Oxidative Stress in Trypanosoma cruzi. |
| Q46510768 | The characterization of anti-T. cruzi activity relationships between ferrocenyl, cyrhetrenyl complexes and ROS release. |
| Q40812626 | Thiosemicarbazone p-Substituted Acetophenone Derivatives Promote the Loss of Mitochondrial Δψ, GSH Depletion, and Death in K562 Cells. |
| Q36076071 | Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers |
| Q41983753 | Toxicity and Loss of Mitochondrial Membrane Potential Induced by Alkyl Gallates in Trypanosoma cruzi |
| Q27653636 | Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit |
| Q37086096 | Trypanosoma cruzi antioxidant enzymes as virulence factors in Chagas disease |
| Q35884080 | Trypanosoma cruzi burden, genotypes, and clinical evaluation of Chilean patients with chronic Chagas cardiopathy. |
| Q41286010 | Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice. |
| Q54231304 | Unveiling benznidazole's mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. |
| Q37254872 | Why does GM1 induce a potent beneficial response to experimental Chagas disease? |
| Q27650159 | X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14 -Demethylase (CYP51) |
Search more.